August 12 2017 by Jason Cook
NanoHybrids has released a comprehensive list of all nanoparticles that have been, or are currently approved for therapeutic indications.
Titled Nanoparticles Approved in the United States (US) and Europe (EU) for Medical Applications, the list contains 60 nanoparticle drugs for various disease indications that have been approved for marketing in the US and Europe.
Preview of FDA/EMA Cleared Nanoparticles for the Treatment of Disease Indications. (Click the above image, or click here to view the complete list and find downloadable versions)
Highlights from the list include:
- The first nanoparticle therapy - INFeD® - was approved by the FDA in 1974 to treat iron deficiency induced anemia.
- 8 of the 60 approved nanoparticle drugs (13%) have either been discontinued, recalled, or abandoned in the last decade.
- Indications for nanoparticle drugs have a large range including: Flu, Schizophrenia, Cancers, Iron Deficiency, Bone Growth, ADHD, Diabetes, MS, Hepatitis, Macular Degeneration, Arthritis, Crohns Disease, High Cholesterol, and more.
More Nanoparticles Set to Gain Approval:
With many more nanoparticle therapies in clinical development, there are sure to be significant additions to the list of approved nanoparticles in the next 5 to 10 years. As new nanoparticles gain approval, or marketing status changes for existing therapies, NanoHybrids will be sure to update this list. So check back often for the latest changes.
To see the entire list or download a copy: click here